MethylGene :: 2008







		2010 news releases

		2009

		2008

		2007

		2006

		2005

		2004

		2003

		2002

2008

November 26, 2008	MethylGene to present at investor conferences
November 10, 2008	MethylGene reports third quarter 2008 financial results
October 27, 2008	MethylGene presents preclinical MGCD290 data at joint ICAAC/IDSA annual meeeting
October 27, 2008	MethylGene reacquires rights to MGCD0103 from Celgene and implements strategic plan
October 23, 2008	MethylGene to present at BIO Investor Forum
October 22, 2008	MethylGene presents MGCD265 preclinical biomarker data at EORTC-NCI-AACR symposium
October 15, 2008	MethylGene initiates Phase I clinical study with MGCD290 for fungal infections
October 2, 2008	MethylGene receives clinical trial approval for MGCD290
September 19, 2008	MethylGene exercises right to convert MGCD0103 collaboration with Celgene to pre-determined royalty and milestone arrangement
August 15, 2008	MethylGene provides update on suspension of new enrollment in MGCD0103 clinical trials
July 30, 2008	MethylGene reports second quarter 2008 financial results
July 29, 2008	MethylGene to present at upcoming investor conferences
July 22, 2008	MethylGene and Celgene announce precautionary suspension
June 25, 2008	MethylGene announces the initiation of a Phase II MGCD0103 randomized, three-arm trial in combination with Vidaza (Trial 013) in patients with high-risk MDS or AML
June 12, 2008	MethylGene initiates second Phase I clinical trial with MGCD265 in solid tumors
June 11, 2008	MethylGene to present at the 2008 BIO Business Forum
June 5, 2008	MethylGene to present at the 7th Annual Needham�Conference
June 3, 2008	Clinical data from a phase II study evaluating MGCD0103 in non-Hodgkin lymphomas (Trial 008) presented at ASCO
June 2, 2008	MethylGene Reports Clinical Data for Hodgkin Lymphoma (Trial 010) and Pancreatic Cancer (Trial 006) at ASCO
May 16, 2008	Clinical data for MGCD0103 to be presented at ASCO
May 12, 2008	MethylGene reports first quarter 2008 finanical results
April 30, 2008	MethylGene to present at BioFinance 2008
April 16, 2008	MethylGene initiates MGCD265 Phase I clinical trial
April 16, 2008	MethylGene presents preclinical data for MGCD265 at the AACR annual meeting
April 15, 2008	MethylGene provides update on its MGCD0103 HDAC inhibitor collaboration with Celgene
April 14, 2008	MethylGene presents clinical biomarker data for MGCD0103 and preclinical efficacy data in combination with taxanes at AACR annual meeting
April 4, 2008	MethylGene announces AGM and corrects previously announced interim Trial 005 data
March 27, 2008	MethylGene announces worldwide collaboration with Otsuka Pharmaceutical Co. Ltd.
March 7, 2008	Fourth quarter and full year 2007 financial results
February 29, 2008	MethylGene fourth quarter and year-end 2007 conference call notice
February 14, 2008	MethylGene announces U.S. orphan drug designation granted by the FDA for MGCD0103 in�acute myelogenous leukemia (AML)
February 11, 2008	MethylGene announces orphan drug designation by the EMEA for MGCD0103 in acute myelogenous leukemia (AML)
February 6, 2008	MethylGene exercises right to opt-out of HDAC neurodegenerative collaboration with EnVivo Pharmaceuticals
February 5, 2008	MethylGene to present at BioCEO & Investor Conference
January 28, 2008	MethylGene reports MGCD0103/Gemzar data at the 2008 GI Symposium (Trial 006)
January 24, 2008	MethylGene to present at Wachovia Healthcare Conference
January 9, 2008	MethylGene and Pharmion start Phase II combination clinical trial with MGCD0103 and Vidaza in patients with relapsed or refractory�Hodgkin lymphoma�or�non-Hodgkin lymphoma (Trial 012)
January 4, 2008	MethylGene files IND for MGCD265, a multi-targeted�kinase inhibitor for cancer

Disclaimer